Filtered By:
Condition: Heart Valve Disease

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 554 results found since Jan 2013.

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
The objective of this study was to compare effectiveness and safety between reduced dose DOACs and high TTR warfarin treatment (TTR  ≥ 70%) in NVAF. A Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 40,564 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) (11,083 patients) or warfarin treatment (29,481 patients ) after exclusion of 374,135 patients due to not being warfarin or DOAC naïve, not being prescribed reduced dose, having previous mechanical heart valve (MHV), or being under 18 years old. The me...
Source: Journal of Thrombosis and Thrombolysis - January 6, 2023 Category: Hematology Source Type: research

Nationwide experience with transcarotid transcatheter aortic valve implantation: Insights from the POL-CAROTID registry
CONCLUSIONS:: The results of the study indicated that the first cohort of transcarotid transcatheter heart valves of second-generation implantations in Poland were associated with a similar prognosis to TF-TAVI with regard to safety and feasibility. TC access may be considered an optimal alternative for patients, in whom the TF approach is precluded.PMID:36594529 | DOI:10.33963/KP.a2022.0288
Source: Kardiologia Polska - January 3, 2023 Category: Cardiology Authors: Radoslaw Wilimski Zenon Huczek Kajetan Grodecki Janusz Kochman Bartosz Rymuza Wojciech Wojakowski Damian Hudziak Dariusz Jagielak Jerzy Sacha Marek Grygier Andrzej Walczak Piotr Hendzel Romuald Cicho ń Marcin Grabowski Mariusz Ku śmierczyk Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Clinical outcomes of the ACURATE  neo2 transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study
CONCLUSIONS: The study results support the safety and efficacy of TAVI with ACURATE neo2 in patients in routine clinical practice.PMID:36440588 | DOI:10.4244/EIJ-D-22-00914
Source: EuroIntervention - November 28, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Won-Keun Kim Corrado Tamburino Helge M öllmann Matteo Montorfano Julia Ellert-Gregersen Tanja K Rudolph Nicolas M Van Mieghem Michael Hilker Ignacio J Amat-Santos Christian Juhl Terkelsen Anna Sonia Petronio Pieter R Stella Matthias G ötberg Andreas R à Source Type: research

Engineering a New Polymeric Heart Valve Using 3D Printing-TRISKELION
Conclusions: The development of a heart valve with a central structure proves to be a promising concept. It offers another principle to address the problem of longevity in currently used heart valves. Using 3D printing to develop new prototypes provides a fast, effective, and accurate way to deepen understanding of its physical properties and requirements. This opens the door for translating and combining results into modern prototypes using highly biocompatible polymers, internal structures, and advanced valve layouts.PMID:36422234 | DOI:10.3390/medicina58111695
Source: Medicina (Kaunas) - November 24, 2022 Category: Universities & Medical Training Authors: Philip Tschorn Filip Schr öter Martin Hartrumpf Ralf-Uwe K ühnel Roya Ostovar Johannes M Albes Source Type: research

Can Warfarin be replaced by non-vitamin K anticoagulants in prosthetic valves?
In this report, the authors discussed the published data related to NOACs use in prosthetic valves highlighting the proposed mechanisms of NOACs failure and other controversial data regarding their efficacy and safety in prosthetic valves.EXPERT OPINION: Although NOACs have proven to be even safer and more effective alternatives to vitamin K antagonists (VKAs) in several indications for anticoagulation, the data regarding their safety and efficacy in prosthetic heart valves is still debatable. The controversial data regarding NOACs use in prosthetic valves renders it difficult to define specific guideline-recommendation fo...
Source: Expert Review of Cardiovascular Therapy - November 24, 2022 Category: Cardiology Authors: Mahmoud Abdelnabi Juthipong Benjanuwattra Ashraf Ahmed Abdallah Almaghraby Source Type: research